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Abstract
Objective: Defects in the human thyroid peroxidase (TPO) gene are reported to be one of the causes of
congenital hypothyroidism (CH) due to a total iodide organification defect. The aim of the present
study was to determine the nature and frequency of TPO gene mutations in patients with CH, charac-
terised by elevated TSH levels and orthotopic thyroid gland, identified in the Portuguese National Neo-
natal Screening Programme.
Subjects and methods: The sample comprised 55 patients, from 53 unrelated families, with follow-up in
the endocrinology clinics of the treatment centres of Porto and Lisbon. Mutation screening in the TPO
gene (exons 1–17) was performed by single-strand conformational analysis followed by sequencing of
fragments with abnormal migration patterns.
Results: Eight different mutations were detected in 13 patients (seven homozygotes and six compound
heterozygotes). Novel mutations included three missense mutations, namely 391T . C (S131P),
1274A . G (N425S) and 2512T .A (C838S), as well as the predictable splice mutation
2748G . A (Q916Q/spl?). The undocumented polymorphism 180-47A . C was also detected.
Conclusion: The results are in accordance with previous observations confirming the genetic hetero-
geneity of TPO defects. The proportion of patients in which the aetiology was determined justifies the
implementation of this molecular testing in our CH patients with dyshormonogenesis.
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Introduction
The latest annual report by the committee of the Portu-
guese National Neonatal Screening Programme indi-
cates that the incidence of congenital hypothyroidism
(CH) in Portugal is approximately 1/3238 newborns
(1). Prior to the implementation of this screening pro-
gramme (presently with a coverage rate of around
99.5%), CH was one of the most frequent causes of
mental retardation in children. CH includes different
clinical entities and, in the majority of cases, is a conse-
quence of thyroid dysgenesis, in which the gland is
either absent (thyroid agenesis) or located ectopically
and/or severely reduced in size (hypoplasia). It is esti-
mated that 15% of CH cases occur as a consequence
of defects in the biochemical mechanisms responsible
for thyroid hormone biosynthesis (thyroid dyshormo-
nogenesis) in which human thyroid peroxidase (TPO)
plays an essential role (2). Many patients with total
iodide organification defect have been shown to have
mutations in the TPO gene (3–15). TPO is a mem-
brane-linked haemoprotein located at the apical
membrane of the thyroid cells; it catalyses the
iodination and subsequent coupling of tyrosine residues
in thyroglobulin, resulting in the synthesis of the thyr-
oid hormones tri-iodothyronine and thyroxine (T4).
The human TPO gene is located on chromosome
2p25 (16) and consists of 17 exons that span 150 kb,
while the respective full-length mRNA is about 3 kb
long (17). Other genes thought to be implicated in
this form of CH include the thyroglobulin (TG) gene
(2), the sodium symporter (NIS) gene (18), the pendrin
gene (PDS) (19) and, more recently, thyroid oxidase
gene 2 (THOX2) (20). In the present study, we screened
for TPO gene mutations in 55 CH patients presenting
elevated thyroid-stimulating hormone (TSH) levels
and orthotopic thyroid gland.
Subjects and methods
Patients
Since the implementation of the National Neonatal
Screening Programme in Portugal, 723 cases of CH
have been detected (1). Diagnosis of CH is based on
elevated TSH levels (cut-off value 20mU/ml) and
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decreased T4 levels (normal .6.5mg/dl), ascertained
in heel puncture blood samples collected on S&S 903
filter paper (Schleicher and Schuell GmbH, Dassel,
Germany) between the 4th and 7th day of life.
Mutation screening was performed on a group of CH
patients with elevated TSH levels at the time of diagno-
sis and orthotopic thyroid gland. The perchlorate dis-
charge test, which aids in the recognition of iodide
organification defects, is not routinely performed; as
such, elevated plasma Tg concentrations were also con-
sidered in the selection of patients, so as to exclude
cases likely to result from defects in Tg synthesis or
TSH receptor inactivation. The selected 55 patients
were members of 53 apparently unrelated families,
none of whom had any knowledge of consanguinity.
Informed consent was obtained from the patients or,
in the case of minors, from their parents.
Genomic analysis
DNA was isolated from peripheral blood according to
the salting out method (21). The 17 exonic regions of
the TPO gene were amplified by PCR with primers as
described previously (5). The PCR reaction mixture
contained 25ml of a 2 £ PCR master mix (Promega
Corporation, Madison, WI, USA), 1 pmol each of for-
ward and reverse primers, 1ml genomic DNA (50 –
250 ng) and nuclease-free water to a final volume of
50ml. The PCR reactions were performed in a 9600
thermal cycler (Applied Biosystems, Foster City, CA,
USA) with an initial denaturation step of 10 min at
94 8C, followed by 35 cycles consisting of denaturation
at 94 8C for 1 min, annealing at 57 8C for 1 min and
extension at 72 8C for 1 min, and with a final extension
at 72 8C for 10 min. The 18 amplicons (exon 8 subdi-
vided into two fragments, 8A and 8B) were subjected
to single-strand conformational analysis (SSCA) using
both the PhastSystem (Pharmacia Biotech) in Phast-
Gels, according to the manufacturer’s instructions,
and a standard vertical electrophoresis system, on
0.5 £ and 1.0 £ MDE gels (FMC Bioproducts, Rock-
land, ME, USA). Gels were stained by standard silver
staining methods. Fragments presenting abnormal elec-
trophoretic mobility were sequenced using the Big Dye
Terminator Kit v2.0 (Applied Biosystems) and capillary
electrophoresis. Because of poor electrophoretic separ-
ation on SSCA, some fragments (8A, 8B and 11)
were also sequenced in all patients. A novel mutation
identified in exon 8 was further characterised by
restriction analysis. This mutation creates a new
restriction site for DdeI. The PCR product of fragment
8B was incubated with DdeI (New England BioLabs,
Beverly, MA, USA) overnight at 37 8C and separated
on a 2% agarose gel.
Population studies
To investigate whether an alteration was a causal
mutation or a common polymorphic variant,
population screens were carried out on 100 healthy
controls, either by SSCA or by differential restriction
analysis. Family co-segregation studies were performed
whenever possible.
Data analysis
The novel predicted splice site mutation, 2748G . A,
was run on the GENSCAN program which predicts
the locations and exon –intron structures of genes
(http://genes.mit.edu/GENSCAN.html). For the novel
missense mutations, phylogenetic conservation of the
amino acid sequences among the peroxidase superfam-
ily was assessed with the aid of the CLUSTAL program
(http://www.ebi.ac.uk/servicestmp/clustalw).
Results and discussion
Mutation analysis of the TPO gene
In all, eight different mutations and 15 polymorphisms
were detected in this group of patients. Novel altera-
tions included three missense and one putative splice
mutation, as well as a silent A to C transversion in
intron 3 (180-47A . C). In 13 of the 55 patients, dele-
terious mutations were identified in both alleles. Clini-
copathologic and mutation data are summarised in
Tables 1 and 2. Sequence analysis of exon 8 revealed
a homozygous GGCC duplication at nucleotide position
1187 in two unrelated patients (1a and 2a). This
mutation has been described previously (3) and leads
to a frameshift with a termination signal in exon 9.
The same duplication (1183_1186dupGGCC) was
also found in the affected siblings of family 3, in hetero-
zygosity with 1978C . G, a documented missense
mutation in exon 11 which results in a glutamine to
glutamic acid substitution at amino acid position 660
(Q660E) (10). Further investigation in other members
of the family revealed that the father carried the
1183_1186dupGGCC mutation, while the mother
and four unaffected sisters were carriers of the Q660E
mutation. The patient in family 4 was found to be het-
erozygous for Q660E and a novel missense mutation in
exon 8, where an A to G transition at nucleotide pos-
ition 1274 results in an aspargine to serine change at
codon 425 (Fig. 1). This alteration creates a new
restriction site for DdeI, such that the 480 bp amplicon
encompassing exon 8 is cut into fragments of 322 and
158 bp (Fig. 1C). Restriction analysis with DdeI was
thus used to screen 100 healthy controls, none of
whom presented this base change. Only the patient’s
mother was available for sequence analysis, and she
was found to carry the new N425S mutation. SSCA
of exon 9 revealed an aberrant conformer in patient
5a. Both parents were heterozygous for this abnormal
fragment, while an unaffected sister presented only
the normal migration pattern. Sequence analysis
showed a homozygous, known missense mutation at
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position 1477 with a nucleotide change from G to A,
resulting in a glycine to serine substitution at codon
493. Patient 6a was homozygous for the documented
mutation Q660E that is also present in compound het-
erozygosity in the affected siblings of families 3 and 10.
In the patient of family 7, a mobility shift in exon 14
led to the identification of homozygosity for the known
single base pair deletion 2422delT (11). This frameshift
mutation, which results in a premature stop codon, was
found in heterozygosity in both parents and in one of
two unaffected brothers. Patient 8a was also hetero-
zygous for this frameshift mutation and the novel
mutation in exon 5: a T to C transition at nucleotide
391 that replaces a serine at codon 131 with a proline
(S131P). Both affected siblings of family 9 were found
to be homozygous for a novel missense mutation in
exon 14: a T to A transition at nucleotide 2512, result-
ing in a cysteine to serine substitution at codon 838
(C838S). The parents were heterozygous for this
mutation. Finally, two other affected siblings (family
10) were found to be compound heterozygotes for
Q660E and a novel point mutation, 2748G . A, in
exon 16 (Fig. 2). This novel mutation, silent at the
amino acid level (Q916Q), was located at position 21
of the 50 (donor) splice site consensus sequence in exon
16 and thus putatively affects splicing. The father is a
carrier of this novel mutation in exon 16 and the
mother carries the known mutation in exon 11.
Deleterious effect of the novel identified
mutations
No thyroid tissue was available for the functional
studies of the peroxidases with the four novel
mutations. The deleterious effect of the missense
mutations was therefore evaluated by assessing the
degree of evolutionary conservation of the respective
amino acids, among several human and other
animal wild-type peroxidases (Table 3). This approach
of multiple sequence alignment indicated that N425
and some neighbouring residues are well conserved
among the peroxidase superfamily. C838 is similarly
well conserved among the TPOs of different species
but has no counterpart in human mieloperoxidase
(MPO), lactoperoxidase (LPO) or eosinofil peroxidase
(EPO), or in bovine lactoperoxidase. The region
Table 2 Description of TPO mutations in the 13 CH patients.
Exon Mutationa
Effect of the mutation
on protein synthesis Reference Frequency of mutant allelesb
5 391T . C S131P Present study 1/110
8 1183_1186dupGGCC N396fsX76 3 6/110
8 1274A . G N425S Present study 1/110
9 1477G . A G493S 15 2/110
11 1978C . G Q660E 10 7/110
14 2422delT C808fsX23 11 3/110
14 2512T . A C838S Present study 4/110
16 2748G . A Spl? Present study 1/110
a The first A in the TPO start codon considered as position 1.
b Frequency amongst the 55 patients (110 alleles).
Table 1 Clinicopathological characteristics of the CH patients (ten families) with TPO mutations identified in this study.
Family/
patient Sex
Current age
(years) Thyroid gland
TSH*
(mU/ml)
T4*
(mg/dl)
Tg
(ng/ml) Identified mutations
1/a F 7 Goiter 215 0.7 299 [1183_1186dupGGCC] þ [1183_1186dupGGCC]
2/a F 2 Goiter 195 2.9 955 [1183_1186dupGGCC] þ [1183_1186dupGGCC]
3/a F 32 Goiter ND ND ND [1183_1186dupGGCC] þ [1978C . G]
3/b F 13 Goiter 235 1.9 79.7 [1183_1186dupGGCC] þ [1978C . G]
4/a F 19 Goiter 81 3.6 ND [1274A . G] þ [1978C . G]
5/a M 11 Goiter 109.6 1.2 1344 [1477G . A] þ [1477G . A]
6/a F 5 Goiter 285 2.8 731 [1978C . G] þ [1978C . G]
7/a F 18 Goiter 192 0.6 ND [2422delT] þ [2422delT]
8/a M 3 Goiter 258 0.5 416 [2422delT] þ [391T . C]
9/a M 5 Goiter 328 2.9 2356 [2512T . A] þ [2512T . A]
9/b M 3 Goiter 378 1.8 1758 [2512T . A] þ [2512T . A]
10/a F 7 Normal 288 0.7 640 [1978C . G] þ [2748G . A]
10/b F 3 Normal 35.8 3.7 ND [1978C . G] þ [2748G . A]
Normal values ,20 6.5–17 3–52
* The levels of T4 and TSH at the 4th–7th day of life.
ND, not determined.
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encoded by exons 8, 9 and 10 is thought to be the
catalytic centre of the TPO protein and several deleter-
ious mutations in these exons have been reported
(5–7, 11, 12, 15). The missense mutation N425S
described here also falls within this domain. An
acidic to neutral amino acid change is likely to influ-
ence the electron transfer environment and conse-
quently the enzymatic activity of the protein. Besides
the membrane spanning region encoded by exon 15
(7), little is known about the carboxyl terminus of
TPO, where the relationship between function and
structure is poorly understood. Mutations in this
area have been reported in several patients with
severe thyroid function (3, 5, 7, 9, 12–15). The
region encoded by exon 14 bears significant simi-
larities to the epidermal growth factor (EGF)-like
potential calcium binding domain (15), where there
are three disulphide bonds, one of which is formed
between residues C825 and C838. The latter is precisely
the residue which is altered in the novel mutation
described here (C838S). The substitution of cysteine
by serine disables the formation of the disulphide
Figure 1 Novel heterozygous mutation in exon 8 (1274A . G)
found in patient 4a that was compound heterozygous for this and
the known mutation Q660E. (A) Pedigree of the affected family.
(B) Sequence analysis of exon 8 revealing heterozygosity for an
A to G transition at nucleotide 1274 which results in an amino
acid exchange from glycine to serine at codon 425. (C) Restriction
analysis of exon 8 (fragment 8B) with DdeI. The mutation
creates a restriction site in the 480 bp fragment, which is
demonstrated by the two fragments of 322 and 158 bp; C1, undi-
gested control amplicon; C2, digested control amplicon; ?, not
analysed.
Figure 2 Novel heterozygous mutation in exon 16 (2748G . A)
found in two siblings of family 10 that were compound hetero-
zygotes for this and the known mutation Q660E. (A) Pedigree
of the affected family. (B) SSCA of exon 16 showing the altered
migratory pattern in both patients and in their father. (C) Sequence
analysis revealing a G to A transition at nucleotide 2748, silent at
amino acid level but predictably affecting splicing.
Table 3 Comparison of amino acid sequences among various
peroxidases coincident with mutations N425S and C838S.
Mutant TPO K A L S425 A H W G R T S838 V D S
Human TPO (17) K A L N425 A H W G R T C838 V D S
Pig TPO (22) K A L N424 A H W G R T C837 V D A
Mouse TPO (23) K A I N413 K H W G K T C826 I D S
Rat TPO (24) K A I N413 T H W G K T C826 I D S
Human MPO (25) K S L N434 P R W *
Human LPO (26) K R L N401 P Q W *
Bovine LPO (26) K K L N401 P H W *
Human EPO (27) R R L N406 P R W *
* No C838 counterpart found in these peroxidases. Highly conserved amino
acids are expressed in bold.
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bond and may thus disrupt the tertiary structure of
the EGF-like potential calcium-binding domain. The
novel mutation S131P, identified in exon 5, is likely
to disrupt the potential glycosylation site at N129
(29), since the acceptor sequence required for N-glyco-
sylation, namely N-X-S/T is modified to N-X-P. Studies
have shown that N-glycans play an essential role in
the correct folding, intracellular trafficking and
activity of TPO (30). The novel mutation identified
in exon 16 (2748G . A) is located at position 21
of the 50 (donor) consensus splice site. Krawczak et al.
(28) have reported a 97% consensus value for this
residue in a similar sequence context. The GENSCAN
program (31), that is designed to predict complete
gene structures in genomic sequences, attributes a
log-odds score of 220 for splicing with this base
change, providing further evidence that the mutation
abolishes splice site recognition. In all four cases, co-
segregation analyses were consistent with a causal
nature of the new mutations. Moreover, they were
not detected in 100 healthy controls (200 alleles), as
opposed to the hitherto undocumented polymorphism
180-47A . C, which was found in 19% of the normal
control alleles.
General remarks
In the 13 patients with TPO mutations, the most preva-
lent mutation was Q660E, previously reported in a Bra-
zilian patient (10). It was found in a homozygous state
in patient 6 and in compound heterozygosity in
patients 3a, 3b, 4a, 10a and 10b. A similar prevalence
was noted for the 1183_1186dupGGCC mutation (six
alleles of the 13 patients with TPO mutations), also
reported to be the most prevalent among Dutch
patients (11). The severity of these two mutations is evi-
dent in family 3 where the older sibling 3a, who had
not received L-thyroxine therapy, was severely affected
with mental retardation. In the same line of reasoning,
one may speculate that the novel predictive splice
mutation described here (2748G . A) is somewhat
milder, since, in contrast with the other patients,
neither affected sibling in family 10 presented goiter.
Analysis of human TPO mRNA in these patients
would help to elucidate the consequence of the splicing
error (exon skipping and/or resort to cryptic splice sites,
and resulting reading frame). This is the first molecular
characterisation ever performed in a cohort of Portu-
guese CH patients in order to establish the aetiology
of CH due to a dyshormonogenic defect. The exception-
ally large proportion of patients found to have TPO
mutations (approximately 24% of our sample) justifies
the implementation of routine molecular testing in
our CH neonates, with immediate benefits in terms of
counselling and monitoring of future pregnancies,
and with the foreseeable future benefit of aetiology-
based differential treatment.
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